-
Je něco špatně v tomto záznamu ?
One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge
N. Majtanova, A. Takacova, V. Kurilova, L. Hejsek, J. Majtan, P. Kolar
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
Springer Journals Complete - Open Access
od 2012-12-01
Springer Nature OA/Free Journals
od 2012-12-01
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. METHODS: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. RESULTS: Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. CONCLUSIONS: PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25001886
- 003
- CZ-PrNML
- 005
- 20250123101952.0
- 007
- ta
- 008
- 250117s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40123-024-01074-y $2 doi
- 035 __
- $a (PubMed)39576486
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Majtanova, Nora $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia. nora.majtanova@gmail.com $1 https://orcid.org/0000000297942277
- 245 10
- $a One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge / $c N. Majtanova, A. Takacova, V. Kurilova, L. Hejsek, J. Majtan, P. Kolar
- 520 9_
- $a INTRODUCTION: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. METHODS: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. RESULTS: Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. CONCLUSIONS: PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Takacova, Adriana $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia
- 700 1_
- $a Kurilova, Veronika $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia $1 https://orcid.org/0000000187915761
- 700 1_
- $a Hejsek, Libor $u Department of Ophthalmology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, 500 05, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000199738969 $7 mzk2007408327
- 700 1_
- $a Majtan, Juraj $u Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska Cesta 21, 845 51, Bratislava, Slovakia. juraj.majtan@savba.sk $u Department of Microbiology, Faculty of Medicine, Slovak Medical University, 833 03, Bratislava, Slovakia. juraj.majtan@savba.sk $1 https://orcid.org/0000000272681584 $7 xx0106600
- 700 1_
- $a Kolar, Petr $u Department of Ophthalmology, Slovak Medical University and University Hospital in Bratislava, Antolska 11, 851 07, Bratislava, Slovakia $1 https://orcid.org/0000000337094648 $7 xx0037722
- 773 0_
- $w MED00210137 $t Ophthalmology and therapy $x 2193-8245 $g Roč. 14, č. 1 (2025), s. 153-167
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39576486 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123101946 $b ABA008
- 999 __
- $a ok $b bmc $g 2254417 $s 1237889
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 14 $c 1 $d 153-167 $e 20241122 $i 2193-8245 $m Ophthalmology and therapy $n Ophthalmol Ther $x MED00210137
- LZP __
- $a Pubmed-20250117